Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
BUSINESS
Amgen Rolls Out Imdelltra for SCLC in Japan
Amgen launched its bispecific antibody Imdelltra (tarlatamab) for the treatment of small cell lung cancer (SCLC) in Japan on April 16 upon its addition to the NHI reimbursement price list. The drug was approved in late December for the indication…
To read the full story
Related Article
- Oncologist Hails Amgen’s Imdelltra as “First New Option in 20 Years” for SCLC
June 23, 2025
- Amgen’s Imdelltra, CSL’s Andembry to Join NHI Price List on April 16
April 10, 2025
- Japan Approves Zepbound, Qalsody, and Lots More Drugs
December 27, 2024
- Amgen Files BiTE Drug Tarlatamab for Lung Cancer in Japan
May 16, 2024
BUSINESS
- Roche Proposes Ex-Takeda CEO Weber for Board
September 24, 2026
- Moderna Launches XFG-Updated mNEXSPIKE in Japan
September 24, 2026
- FDA Accepts Tanabe’s EPP/XLP Drug for Priority Review
September 24, 2026
- GenAI Use at Japan Pharmas Rises to 92% in 2026: Funlead Survey
September 24, 2026
- Japan OKs FoundationOne CDx for Pfizer’s Lorbrena
September 24, 2026
Japan is ramping up its push to spread regional formularies nationwide, a policy expected to standardize treatments, strengthen supply resilience,…
We had just gotten off a call with a client in Europe, and we’d received a bit of an earful. “Philip,” the client pressed, “what can this candidate bring to us? We know what he does, but what has he…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…